Lindegaard Birgitte, Frøsig Christian, Petersen Anne Marie W, Plomgaard Peter, Ditlevsen Susanne, Mittendorfer Bettina, Van Hall Gerrit, Wojtaszewski Jørgen F P, Pedersen Bente K
Centre of Inflammation and Metabolism, Department of Infectious Diseases, Rigshospitalet, Copenhagen Ø, Denmark.
Diabetes. 2007 Aug;56(8):2070-7. doi: 10.2337/db07-0144. Epub 2007 Jun 29.
HIV-infected patients with lipodystrophy (HIV lipodystrophy) are insulin resistant and have elevated plasma free fatty acid (FFA) concentrations. We aimed to explore the mechanisms underlying FFA-induced insulin resistance in patients with HIV lipodystrophy. Using a randomized, placebo-controlled, cross-over design, we studied the effects of an overnight acipimox-induced suppression of FFAs on glucose and FFA metabolism by using stable isotope-labeled tracer techniques during basal conditions and a two-stage euglycemic-hyperinsulinemic clamp (20 and 50 mU insulin/m(2) per min, respectively) in nine patients with nondiabetic HIV lipodystrophy. All patients received antiretroviral therapy. Biopsies from the vastus lateralis muscle were obtained during each stage of the clamp. Acipimox treatment reduced basal FFA rate of appearance by 68.9% (95% CI 52.6-79.5) and decreased plasma FFA concentration by 51.6% (42.0-58.9) (both, P < 0.0001). Endogenous glucose production was not influenced by acipimox. During the clamp, the increase in glucose uptake was significantly greater after acipimox treatment compared with placebo (acipimox: 26.85 micromol x kg(-1) x min(-1) [18.09-39.86] vs. placebo: 20.30 micromol x kg(-1) x min(-1) [13.67-30.13]; P < 0.01). Insulin increased phosphorylation of Akt Thr(308) and glycogen synthase kinase-3beta Ser(9), decreased phosphorylation of glycogen synthase (GS) site 3a + b, and increased GS activity (percent I-form) in skeletal muscle (P < 0.01). Acipimox decreased phosphorylation of GS (site 3a + b) (P < 0.02) and increased GS activity (P < 0.01) in muscle. The present study provides direct evidence that suppression of lipolysis in patients with HIV lipodystrophy improves insulin-stimulated peripheral glucose uptake. The increased glucose uptake may in part be explained by increased dephosphorylation of GS (site 3a + b), resulting in increased GS activity.
患有脂肪代谢障碍的HIV感染患者(HIV脂肪代谢障碍)存在胰岛素抵抗,且血浆游离脂肪酸(FFA)浓度升高。我们旨在探究HIV脂肪代谢障碍患者中FFA诱导胰岛素抵抗的潜在机制。采用随机、安慰剂对照、交叉设计,我们在基础状态下以及两阶段正常血糖-高胰岛素钳夹试验(分别为20和50 mU胰岛素/m²每分钟)期间,使用稳定同位素标记示踪技术,研究了阿西莫司过夜诱导的FFA抑制对9例非糖尿病HIV脂肪代谢障碍患者葡萄糖和FFA代谢的影响。所有患者均接受抗逆转录病毒治疗。在钳夹试验的每个阶段均获取股外侧肌活检样本。阿西莫司治疗使基础FFA出现率降低68.9%(95%可信区间52.6 - 79.5),血浆FFA浓度降低51.6%(42.0 - 58.9)(两者均P < 0.0001)。阿西莫司对内源性葡萄糖生成无影响。在钳夹试验期间,与安慰剂相比,阿西莫司治疗后葡萄糖摄取增加显著更大(阿西莫司:26.85微摩尔×千克⁻¹×分钟⁻¹[18.09 - 39.86] 对 安慰剂:20.30微摩尔×千克⁻¹×分钟⁻¹[13.67 - 30.13];P < 0.01)。胰岛素增加了骨骼肌中Akt Thr(308)和糖原合酶激酶-3β Ser(9)的磷酸化,降低了糖原合酶(GS)位点3a + b的磷酸化,并增加了GS活性(I型百分比)(P < 0.01)。阿西莫司降低了肌肉中GS(位点3a + b)的磷酸化(P < 0.02)并增加了GS活性(P < 0.01)。本研究提供了直接证据,即抑制HIV脂肪代谢障碍患者的脂肪分解可改善胰岛素刺激的外周葡萄糖摄取。葡萄糖摄取增加部分可能是由于GS(位点3a + b)去磷酸化增加,导致GS活性增加。